ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD79b
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD79b
3
trial(s) found.
NCT06788509
Advanced
Phase 1
Enrolling by invitation
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring (
PLATFORMPACAN1001
)
BTK inhibitor
Ibrutinib
JNJ-80948543
MALT1 inhibitor
Rezetamig
Safimaltib
bispecific T-cell engager,CD22-targeting
cancer therapy
cancer therapy,BTK-targeting
cancer therapy,CD20-targeting
cancer therapy,CD22-targeting
cancer therapy,CD79b-targeting
cancer therapy,MALT1-targeting
immuno-oncology therapy,CD20-targeting
immuno-oncology therapy,CD22-targeting
immuno-oncology therapy,CD79b-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
trispecific CD79b/CD20/CD3 antibody
+ cancer therapy,CD79b-targeting
Cancer
Castrate-resistant prostate cancer
Leukaemia
Lymphoma
Myelodysplastic syndrome
Solid tumour
WA
6009 - Nedlands - Linear Clinical Research
NCT04884035
Paed
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
+ anti-CD79b antibody-drug conjugate
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, =80 Years, or Frail =75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Enrolling by invitation (1)
Recruitment Country and State
WA (3)
NSW (2)
SA (1)
ACT (1)
NZ (1)
QLD (1)
TAS (1)
VIC (1)
Phase
Phase 1 (2)
Phase 3 (1)
Trial Type
Advanced (1)
Paed (1)
Haem (1)
Cancer Therapy Class
CD20
100%
CD79b
100%
BTK
33%
CD22
33%
MALT1
33%
cereblon
33%
Facility
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
6000 - Perth - Royal Perth Hospital (2)
6009 - Nedlands - Linear Clinical Research (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
Castrate-resistant prostate cancer
Leukaemia
Male genital cancers
Myelodysplastic syndrome
Myeloproliferative neoplasm
Prostate adenocarcinoma
Prostate cancer
Solid tumour
Urogenital cancer
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy